En undersøgelse til undersøgelse (PiNACLE-H2H)
Et fase 3 randomiseret kontrolleret forsøg med Rondecabtagene Autoleucel, en autolog, dobbeltmålrettet CD19/CD20 CAR T-celle produktkandidat, versus efterforskerens valg af CD19 CAR T-cellebehandling hos patienter med tilbagefaldt eller refraktær stort B-celle lymfom i den anden-line indstilling CD19
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
PiNACLE-H2H is a Phase 3 randomized controlled trial comparing the efficacy and safety of rondecabtagene autoleucel (ronde-cel, formerly known as LYL314) against the currently approved cluster of differentiation (CD)19 chimeric antigen receptor (CAR) T-cell therapies (axicabtagene ciloleucel [axi-cel] or lisocabtagene maraleucel [liso-cel]), in patients with aggressive LBCL that has relapsed or is refractory to first-line anti-CD20 antibody and anthracycline-containing chemotherapy.
Patients will be randomized (1:1) before leukapheresis to receive either:
- Ronde-cel; or
- Investigator's choice of axi-cel or liso-cel
Most patients who receive currently approved CD19-directed CAR T-cell therapies, including axi-cel and liso-cel, still experience progressive disease, often due to mechanisms such as CD19 antigen loss or T-cell exhaustion.
Ronde-cel is a novel, autologous, dual-targeting CD19/CD20 CAR T-cell product candidate enriched for CD62L-positive naïve and central memory T cells, which are associated with enhanced proliferation capacity and persistence. Ronde-cel is an "OR"-gated CAR construct that can fully activate upon recognition of either CD19 or CD20, aiming to improve durability of response despite antigen heterogeneity.
Approximately 400 participants will be enrolled. CAR T-cell therapy in both arms will be administered as a single intravenous infusion following fludarabine and cyclophosphamide lymphodepletion. Participants will be followed for 3 years for safety and efficacy, with long-term follow-up extending to 15 years.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Mary Lessig, MS
- Telefonnummer: 000-000-0000
- E-mail: clinicaltrials@lyell.com
Undersøgelse Kontakt Backup
- Navn: James Dean, MD, PhD
- Telefonnummer: 000-000-0000
- E-mail: clinicaltrials@lyell.com
Studiesteder
-
-
Queensland
-
Douglas, Queensland, Australien, 4814
- Rekruttering
- Townsville University Hospital
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- Rekruttering
- The Alfred
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Rekruttering
- Princess Margaret Cancer Centre
-
-
-
-
Arizona
-
Gilbert, Arizona, Forenede Stater, 85234
- Rekruttering
- Banner MD Anderson Cancer Center
-
Scottsdale, Arizona, Forenede Stater, 85258
- Rekruttering
- Honor Health
-
Scottsdale, Arizona, Forenede Stater, 85259
- Rekruttering
- Mayo Clinic Arizona
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72205
- Ikke rekrutterer endnu
- University of Arkansas
-
-
California
-
Los Angeles, California, Forenede Stater, 90048
- Rekruttering
- Cedars-Sinai Medical Center
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- University of California, Los Angeles (UCLA)
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- University of California, Irvine
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- University of Colorado
-
Denver, Colorado, Forenede Stater, 80218
- Rekruttering
- Colorado Blood Cancer Institute
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20007
- Rekruttering
- MedStar Georgetown University Hospital
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32224
- Rekruttering
- Mayo Clinic Florida
-
Orlando, Florida, Forenede Stater, 32804
- Rekruttering
- AdventHealth
-
Tampa, Florida, Forenede Stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30342
- Rekruttering
- Northside Hospital
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- University of Chicago
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Northwestern
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- Rekruttering
- University of Iowa
-
-
Kansas
-
Westwood, Kansas, Forenede Stater, 66205
- Rekruttering
- University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40202
- Rekruttering
- University of Louisville Health
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02111
- Rekruttering
- Tufts Medical Center
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Rekruttering
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68105
- Rekruttering
- University of Nebraska Medical Center (UNMC)
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Rekruttering
- Hackensack
-
Morristown, New Jersey, Forenede Stater, 07960
- Rekruttering
- Atlantic Health
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87102
- Rekruttering
- University of New Mexico Comprehensive Cancer Center
-
-
New York
-
Buffalo, New York, Forenede Stater, 14263
- Rekruttering
- Roswell Park Comprehensive Cancer Center
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27705
- Rekruttering
- Duke Cancer Institute
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Ikke rekrutterer endnu
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45267
- Rekruttering
- University of Cincinnati
-
Cincinnati, Ohio, Forenede Stater, 45242
- Rekruttering
- Oncology Hematology Care Clinical Trials
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Cleveland Clinical Taussig Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15212
- Ikke rekrutterer endnu
- Allegheny Health Network
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Forenede Stater, 78704
- Rekruttering
- St. David's South Austin Medical Center
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- University of Texas Southwestern Medical Center
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- Texas Transplant Institute
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84143
- Rekruttering
- Intermountain Healthcare
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater, 23502
- Rekruttering
- Virginia Oncology Associates
-
Richmond, Virginia, Forenede Stater, 23298
- Rekruttering
- Virginia Commonwealth University-Massey Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Rekruttering
- Medical College of Wisconsin
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
-
CAR T cell naïve and eligible to receive a CD19 CART-cell therapy
-
Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)
- Diffuse large B-cell lymphoma (DLBCL)
- Transformations of indolent B-cell lymphomas (excluding Richter's transformation)
- DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
- High-grade B-cell lymphoma (HGBCL) not otherwise specified (HGBCL NOS)
- Primary mediastinal large B-cell lymphoma (PMBCL)
- Grade 3B follicular lymphoma/large cell follicular lymphoma (FL3B)
-
Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containing first-line chemoimmunotherapy
-
Measurable disease by presence of [18F]-fluorodeoxyglucose PET/CT positive lesion during Screening per Lugano Criteria
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
-
Adequate hematological, renal, hepatic, pulmonary, and cardiac function
Key Exclusion Criteria:
- Patients ineligible to receive CD19 CAR T-cell therapy
- Primary CNS lymphoma
- Patients with primary cutaneous LBCL, human herpes virus-8 positive lymphoma, Burkitt lymphoma, T cell histiocyte-rich lymphoma, or transformation from chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter's transformation)
- Patients with prior history of malignancy, other than aggressive relapsed or refractory LBCL, unless the patient has been free of the disease for ≥ 2 years
- Patients with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment
- Active autoimmune disease requiring ongoing systemic immunosuppressive therapy.
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Rondecabtagene Autoleucel
|
An autologous, dual-targeting CD19/20 CAR T-cell candidate.
Andre navne:
|
|
Aktiv komparator: Investigator's Choice CD19
axicabtagene ciloleucel, lisocabtagene maraleucel |
An autologous CD19 CAR T-cell therapy
Andre navne:
An autologous CD19 CAR T-cell therapy
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Event free survival
Tidsramme: 36 months
|
The time interval from treatment initiation until the occurrence of a specific event of interest. |
36 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Response Rate
Tidsramme: 36 months
|
Best Overall Response per Lugano Criteria |
36 months
|
|
Complete Response Rate
Tidsramme: 36 months
|
Complete Response per Lugano Criteria |
36 months
|
|
Progression Free Survial
Tidsramme: 36 months
|
The length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse. |
36 months
|
|
Overall Survival
Tidsramme: 6 years
|
The length of time from either the date of diagnosis or the start of treatment for a disease, that patients diagnosed with the disease, are still alive. |
6 years
|
|
Incidence and severity adverse events
Tidsramme: 36 months
|
To assess safety defined as type and frequency of AEs, serious adverse events (SAEs), and laboratory abnormalities. |
36 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- LYL314-102
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .